Core Viewpoint - Aquestive Therapeutics, Inc. is actively participating in the Piper Sandler 37th Annual Healthcare Conference, highlighting its commitment to advancing innovative medicines and engaging with investors [1][2]. Company Overview - Aquestive Therapeutics is a pharmaceutical company focused on improving patients' lives through innovative science and delivery technologies, developing orally administered and topical gel products to deliver complex molecules [4]. - The company has four commercialized products marketed by licensees in the U.S. and globally, and it is the exclusive manufacturer of these licensed products [4]. - Aquestive is advancing a late-stage proprietary product candidate for treating severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel for dermatology conditions [4]. Upcoming Events - The management team will hold a fireside chat on December 4, 2025, focusing on the product candidate Anaphylm™ (dibutepinephrine) sublingual film, discussing regulatory progress and commercial readiness [2]. - Investor meetings will also be hosted on the same day, providing opportunities for direct engagement with the management team [2]. Communication and Accessibility - A webcast of the fireside chat will be available on the company's website, with a replay accessible for 30 days post-event [3].

Core Insights - A significant rally occurred in the biotech and healthcare sectors on October 9, with multiple stocks reaching 52-week highs, driven by regulatory milestones, strategic announcements, and investor enthusiasm around clinical progress [1] Company Highlights - Aquestive Therapeutics Inc. (AQST) achieved a 52-week high of $6.86, closing at $6.69, following the announcement of a new U.S. patent for its PharmFilm, enhancing its position in oral drug delivery platforms [2] - Ascendis Pharma A/S (ASND) reached a 52-week high of $216.45, closing at $214.77, coinciding with the submission of a Marketing Authorisation Application to the European Medicines Agency for its investigational therapy targeting achondroplasia in children [3] - Cidara Therapeutics Inc. (CDTX) advanced 12.44% to close at $110.76, hitting a 52-week high of $111.35 after receiving Breakthrough Therapy designation from the FDA for its antiviral candidate CD388 [4] - Intellia Therapeutics Inc. (NTLA) surged 4.05% to end at $25.46, with a new 52-week high of $26.99, driven by optimism surrounding its in vivo CRISPR programs and recent trial updates [5] - Organigram Global Inc. (OGI) gained 4.12% to close at $2.02, reaching a 52-week high of $2.08, following the launch of its new hemp-derived delta-9 brand "happly" targeting mindful recreation consumers [6] - uniQure N.V. (QURE) rose 6.14% to finish at $63.65, with a 52-week high of $65.12, supported by analyst upgrades and renewed interest in its gene therapy candidate for Huntington's disease [7] - REGENXBIO Inc. (RGNX) closed slightly lower at $12.17 but reached a 52-week high of $12.84, presenting interim Phase II data for ABBV-RGX-314 at a major ophthalmology meeting [8] - Tempus AI Inc. (TEM) saw a decline of 3.85% to $99.28 after hitting a 52-week high of $104.32, despite being selected by ARPA-H for a federal precision cancer therapy initiative [9] - Tilray Brands, Inc. (TLRY) jumped 22.09% to close at $2.10, reaching a 52-week high of $2.32, reporting a return to profitability with record quarterly revenue of $210 million [9] - Zenas BioPharma (ZBIO) gained 7.18% to end at $27.76, hitting a 52-week high of $28.72 after announcing a licensing agreement and a $120 million private placement to support its autoimmune pipeline [10] - Brookdale Senior Living Inc. (BKD) rose 9.36% to close at $8.88, reaching a 52-week high of $9.09, reporting its highest occupancy rate in over a year at 82.5% [11]

Core Viewpoint - Aquestive Therapeutics, Inc. is actively engaging with investors through participation in three upcoming conferences in September 2025, showcasing its commitment to transparency and investor relations [1]. Company Overview - Aquestive Therapeutics is a pharmaceutical company focused on advancing medicines that significantly improve patients' lives through innovative science and delivery technologies [2]. - The company is developing orally administered products to deliver complex molecules, providing alternatives to invasive and inconvenient standard therapies [2]. - Currently, Aquestive has four commercialized products marketed by its licensees globally and is the exclusive manufacturer of these products [2]. - The company collaborates with other pharmaceutical firms to bring new molecules to market using proprietary technologies, such as PharmFilm [2]. - A late-stage proprietary product candidate for treating severe allergic reactions, including anaphylaxis, is under development, along with an early-stage epinephrine prodrug topical gel for dermatological conditions like alopecia areata [2]. Upcoming Events - The company will participate in the Cantor Healthcare Conference with a fireside chat scheduled for 8:00 am ET on September 4, 2025, and will host investor meetings on September 3 and 4 [4]. - At the Wells Fargo Healthcare Conference, the company will be available for investor meetings on September 5 [4]. - The H.C. Wainwright 26th Annual Global Investor Conference will feature a presentation at 10:00 am ET on September 9, 2025, with investor meetings available on September 8 and 9 [4].

Company Overview - Aquestive Therapeutics, Inc. is a pharmaceutical company focused on advancing medicines to improve patients' lives through innovative science and delivery technologies [2] - The company develops orally administered and topical gel products to deliver complex molecules, providing alternatives to invasive standard therapies [2] - Currently, Aquestive has four commercialized products marketed by its licensees in the U.S. and globally, and it is the exclusive manufacturer of these products [2] Product Development - The company is advancing a late-stage proprietary product candidate for treating severe allergic reactions, including anaphylaxis [2] - An early-stage epinephrine prodrug topical gel product candidate is also in development for various dermatological conditions, including alopecia areata [2] Upcoming Events - The management team of Aquestive will participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism on July 9, 2025, which will include panels on key therapeutic themes in immunology, inflammation, and metabolism [1]